{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:35:54Z","timestamp":1791286554441,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7121","license":[{"start":{"date-parts":[[2006,11,22]],"date-time":"2006-11-22T00:00:00Z","timestamp":1164153600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1038\/nature05348","type":"journal-article","created":{"date-parts":[[2006,11,22]],"date-time":"2006-11-22T14:19:13Z","timestamp":1164205153000},"page":"949-952","source":"Crossref","is-referenced-by-count":238,"title":["Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine"],"prefix":"10.1038","volume":"444","author":[{"given":"Nikolay O.","family":"Bukanov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine W.","family":"Klinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Ledbetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oxana","family":"Ibraghimov-Beskrovnaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,11,22]]},"reference":[{"key":"BFnature05348_CR1","first-page":"1828","volume-title":"Renal Pathology","author":"LW Welling","year":"1996","unstructured":"Welling, L. W. & Grantham, J. J. in Renal Pathology (eds Tisher, C. & Brenner, B.) 1828\u20131863 (Lippincott, Philadelphia, 1996)"},{"key":"BFnature05348_CR2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1586\/14779072.2.3.369","volume":"2","author":"T Ecder","year":"2004","unstructured":"Ecder, T. & Schrier, R. W. Hypertension and left ventricular hypertrophy in autosomal dominant polycystic kidney disease. Expert Rev. Cardiovasc. Ther. 2, 369\u2013374 (2004)","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"BFnature05348_CR3","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1016\/j.biocel.2004.03.012","volume":"36","author":"PD Wilson","year":"2004","unstructured":"Wilson, P. D. Polycystic kidney disease: new understanding in the pathogenesis. Int. J. Biochem. Cell Biol. 36, 1868\u20131873 (2004)","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"BFnature05348_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/ng0695-151","volume":"10","author":"J Hughes","year":"1995","unstructured":"Hughes, J. et al. The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. Nature Genet. 10, 151\u2013160 (1995)","journal-title":"Nature Genet."},{"key":"BFnature05348_CR5","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.272.5266.1339","volume":"272","author":"T Mochizuki","year":"1996","unstructured":"Mochizuki, T. et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272, 1339\u20131342 (1996)","journal-title":"Science"},{"key":"BFnature05348_CR6","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1086\/340448","volume":"70","author":"LF Onuchic","year":"2002","unstructured":"Onuchic, L. F. et al. PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel \u03b2-helix 1 repeats. Am. J. Hum. Genet. 70, 1305\u20131317 (2002)","journal-title":"Am. J. Hum. Genet."},{"key":"BFnature05348_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/ng833","volume":"30","author":"CJ Ward","year":"2002","unstructured":"Ward, C. J. et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nature Genet. 30, 259\u2013269 (2002)","journal-title":"Nature Genet."},{"key":"BFnature05348_CR8","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1097\/01.ASN.0000141055.57643.E0","volume":"15","author":"GJ Pazour","year":"2004","unstructured":"Pazour, G. J. Intraflagellar transport and cilia-dependent renal disease: the ciliary hypothesis of polycystic kidney disease. J. Am. Soc. Nephrol. 15, 2528\u20132536 (2004)","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnature05348_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/labinvest.3700253","volume":"85","author":"J Pan","year":"2005","unstructured":"Pan, J., Wang, Q. & Snell, W. J. Cilium-generated signaling and cilia-related disorders. Lab. Invest. 85, 452\u2013463 (2005)","journal-title":"Lab. Invest."},{"key":"BFnature05348_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0092-8674(02)00716-X","volume":"109","author":"AK Bhunia","year":"2002","unstructured":"Bhunia, A. K. et al. PKD1 induces p21waf1 and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell 109, 157\u2013168 (2002)","journal-title":"Cell"},{"key":"BFnature05348_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1083\/jcb.200503053","volume":"169","author":"LM Quarmby","year":"2005","unstructured":"Quarmby, L. M. & Parker, J. D. Cilia and the cell cycle? J. Cell Biol. 169, 707\u2013710 (2005)","journal-title":"J. Cell Biol."},{"key":"BFnature05348_CR12","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/368750a0","volume":"368","author":"DD Woo","year":"1994","unstructured":"Woo, D. D., Miao, S. Y., Pelayo, J. C. & Woolf, A. S. Taxol inhibits progression of congenital polycystic kidney disease. Nature 368, 750\u2013753 (1994)","journal-title":"Nature"},{"key":"BFnature05348_CR13","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1432-1033.1997.t01-2-00527.x","volume":"243","author":"L Meijer","year":"1997","unstructured":"Meijer, L. et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243, 527\u2013536 (1997)","journal-title":"Eur. J. Biochem."},{"key":"BFnature05348_CR14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/ijc.10738","volume":"102","author":"SJ McClue","year":"2002","unstructured":"McClue, S. J. et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 102, 463\u2013468 (2002)","journal-title":"Int. J. Cancer"},{"key":"BFnature05348_CR15","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1158\/0008-5472.CAN-05-0233","volume":"65","author":"DE MacCallum","year":"2005","unstructured":"MacCallum, D. E. et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 65, 5399\u20135407 (2005)","journal-title":"Cancer Res."},{"key":"BFnature05348_CR16","first-page":"1311","volume":"5","author":"T Guzi","year":"2004","unstructured":"Guzi, T. CYC-202 Cyclacel. Curr. Opin. Investig. Drugs 5, 1311\u20131318 (2004)","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"BFnature05348_CR17","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1681\/ASN.2006020136","volume":"17","author":"LA Smith","year":"2006","unstructured":"Smith, L. A. et al. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J. Am. Soc. Nephrol. 17, 2821\u20132831 (2006)","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnature05348_CR18","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1101\/gad.11.8.957","volume":"11","author":"JA Diehl","year":"1997","unstructured":"Diehl, J. A., Zindy, F. & Sherr, C. J. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin\u2013proteasome pathway. Genes Dev. 11, 957\u2013972 (1997)","journal-title":"Genes Dev."},{"key":"BFnature05348_CR19","doi-asserted-by":"publisher","first-page":"31208","DOI":"10.1074\/jbc.M500806200","volume":"280","author":"S Bach","year":"2005","unstructured":"Bach, S. et al. Roscovitine targets, protein kinases and pyridoxal kinase. J. Biol. Chem. 280, 31208\u201331219 (2005)","journal-title":"J. Biol. Chem."},{"key":"BFnature05348_CR20","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1681\/ASN.2004090800","volume":"17","author":"S Omori","year":"2006","unstructured":"Omori, S. et al. Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J. Am. Soc. Nephrol. 17, 1604\u20131614 (2006)","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnature05348_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/sj.cdd.4401717","volume":"13","author":"L Lin","year":"2006","unstructured":"Lin, L., Ye, Y. & Zakeri, Z. p53, Apaf-1, caspase-3, and -9 are dispensable for Cdk5 activation during cell death. Cell Death Differ. 13, 141\u2013150 (2006)","journal-title":"Cell Death Differ."},{"key":"BFnature05348_CR22","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1046\/j.1523-1755.2002.00250.x","volume":"61","author":"T Ecder","year":"2002","unstructured":"Ecder, T. et al. Caspases, Bcl-2 proteins and apoptosis in autosomal-dominant polycystic kidney disease. Kidney Int. 61, 1220\u20131230 (2002)","journal-title":"Kidney Int."},{"key":"BFnature05348_CR23","doi-asserted-by":"publisher","first-page":"6954","DOI":"10.1073\/pnas.0408518102","volume":"102","author":"Y Tao","year":"2005","unstructured":"Tao, Y. et al. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease. Proc. Natl Acad. Sci. USA 102, 6954\u20136959 (2005)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature05348_CR24","doi-asserted-by":"publisher","first-page":"8333","DOI":"10.1073\/pnas.0500989102","volume":"102","author":"S Di Giovanni","year":"2005","unstructured":"Di Giovanni, S. et al. Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc. Natl Acad. Sci. USA 102, 8333\u20138338 (2005)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature05348_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0197-0186(03)00147-5","volume":"44","author":"E Verdaguer","year":"2004","unstructured":"Verdaguer, E. et al. Antiapoptotic effects of roscovitine in cerebellar granule cells deprived of serum and potassium: a cell cycle-related mechanism. Neurochem. Int. 44, 251\u2013261 (2004)","journal-title":"Neurochem. Int."},{"key":"BFnature05348_CR26","doi-asserted-by":"publisher","first-page":"9320","DOI":"10.1158\/0008-5472.CAN-05-1276","volume":"65","author":"OM Tirado","year":"2005","unstructured":"Tirado, O. M., Mateo-Lozano, S. & Notario, V. Roscovitine is an effective inducer of apoptosis of Ewing\u2019s sarcoma family tumor cells in vitro and in vivo.. Cancer Res. 65, 9320\u20139327 (2005)","journal-title":"Cancer Res."},{"key":"BFnature05348_CR27","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1046\/j.1523-1755.2003.00232.x","volume":"64","author":"WE Sweeney","year":"2003","unstructured":"Sweeney, W. E. et al. Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability. Kidney Int. 64, 1310\u20131319 (2003)","journal-title":"Kidney Int."},{"key":"BFnature05348_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1681\/ASN.2004080660","volume":"16","author":"Y Tao","year":"2005","unstructured":"Tao, Y., Kim, J., Schrier, R. W. & Edelstein, C. L. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J. Am. Soc. Nephrol. 16, 46\u201351 (2005)","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnature05348_CR29","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.1073\/pnas.0509694103","volume":"103","author":"JM Shillingford","year":"2006","unstructured":"Shillingford, J. M. et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl Acad. Sci. USA 103, 5466\u20135471 (2006)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature05348_CR30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nm1004","volume":"10","author":"VE Torres","year":"2004","unstructured":"Torres, V. E. et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nature Med. 10, 363\u2013364 (2004)","journal-title":"Nature Med."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nature05348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature05348","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature05348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:00:34Z","timestamp":1684418434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature05348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,22]]},"references-count":30,"journal-issue":{"issue":"7121","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["BFnature05348"],"URL":"https:\/\/doi.org\/10.1038\/nature05348","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,22]]}}}